Related Experiment Video

Updated: Aug 29, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Mechanism and inhibition of BRAF kinase

Amber Gunderwala1, Nicholas Cope1, Zhihong Wang1

  • 1Department of Chemistry & Biochemistry, College of Science and Mathematics, Rowan University, Glassboro, NJ, USA.

Current Opinion in Chemical Biology
|September 6, 2022
PubMed

Insights

Structural studies reveal BRAF kinase autoinhibition mechanisms. New inhibitors targeting BRAF or its dimers offer improved cancer drug development for RAF/RAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • The role of BRAF in tumor initiation is established, but its autoinhibition mechanism was recently elucidated through structural studies.
  • These studies revealed how regulatory domains control BRAF kinase activity, enhancing understanding of RAF kinase regulation.
  • BRAF inhibitors targeting BRAFV600E are effective in melanoma but less so in other RAS-driven cancers due to paradoxical MAPK pathway activation.

Purpose of the Study:

  • To provide a comprehensive understanding of BRAF kinase regulation and autoinhibition mechanisms.
  • To discuss the development and limitations of current BRAF inhibitors.
  • To explore novel therapeutic strategies for RAF/RAS-driven cancers.

Main Methods:

  • Structural biology techniques to elucidate BRAF autoinhibition.
  • Analysis of small molecule BRAF inhibitors and their efficacy.
  • Review of emerging inhibitor classes targeting BRAF or its dimer interface.

Main Results:

  • Recent structural studies have uncovered the precise mechanisms of BRAF autoinhibition.
  • BRAF inhibitors targeting BRAFV600E show limitations against other mutants due to paradoxical pathway activation.
  • New generations of inhibitors and dimer interface inhibitors are under development.

Conclusions:

  • A deeper understanding of BRAF regulation is crucial for advancing drug development.
  • Diverse BRAF inhibitors are needed to effectively treat various RAF/RAS-driven cancers.
  • Targeting BRAF dimers represents a promising therapeutic avenue.
Keywords:
14-3-3Allosteric kinase inhibitorAutoinhibitionParadoxical activationRAF kinaseRASRAS-RAF interaction

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.2K
Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development09:32

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

8.8K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K